Ligand Pharmaceuticals to Acquire Apeiron Biologics for €92 Million
Ligand will pay Apeiron shareholders additional consideration based on future commercial and regulatory events, including up to €25.9 million ($28 million) if Qarziba royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. …